This document provides information about an upcoming conference on asthma and COPD drug development taking place June 24-26, 2009 in Philadelphia, PA. Key details include: - Early bird registration by April 3rd can save up to $698. The conference will provide insights into new advances in respiratory drug development. - Over 16 sessions will cover topics like formulating respiratory drug development pipelines, differences between small and large molecules, evolving clinical endpoints, and improving patient management and adherence. - Speakers include leaders from companies like AstraZeneca, Merck, J&J, MedImmune, Schering-Plough, and more. Networking opportunities are available. - Sponsorship and exhibition opportunities

1. Register by April 3rd and SAVE up to $698
Asthma Gain valuable insights into new
groundbreaking advances within the
respiratory drug development market
& COPD
TM
June 24-26, 2009
Philadelphia, PA
See
inside for the
All-Access
Pass discount!
Learn from Leading
Innovators Including:
Heribert Staudinger, PhD, Vice President,
Clinical Development, Schering Plough
Nestor A. Molfino, MD, Vice President, Clinical
Development, Respiratory Diseases, Allergy and
Learn Best Practice Strategies On How To: Inflammation, MedImmune
Theodore F. Reiss, MD, Vice President of Clinical
Assess the need for innovative drug development pipelines in the Research, Merck Research Laboratories
•
respiratory market Adam Wanner, MD, Professor, Principal
Investigator, University of Miami Miller School
Uncover modern techniques for formulating a respiratory drug
• of Medicine
development pipeline Shahin Sanjar, PhD, Head, Pipeline Sourcing,
Nycomed US Inc.
Discover if we need new bronchodilators and anti-inflammatory
•
Mark Parry-Billings, PhD, Chief Executive
drugs for the treatment of Asthma and COPD Officer, Topigen Pharmaceuticals
Develop and enhance product design for addressing patient
• Chris O’Brien, PhD, Vice President, Respiratory &
Inflammation Therapeutic Area, AstraZeneca
adherence and compliance
Kevin B. Bacon, PhD, President, Founder and
Discover effective strategies for improving the management of
•
Chief Scientific Officer, Axikin Pharmaceuticals
patient care in Asthma Colin Scott, MD, Global Brand Medical Director,
Novartis
Michael A. McAlexander, PhD, Senior Research
Fellow, CEDD, GlaxoSmithKline
Media Partners:
Lawrence de Garavilla, PhD, Research Fellow,
Drug Discovery , Inflammation and Pulmonary
Diseases Team, Johnson and Johnson
Jonathan E. Phillips, Ph.D, Principal Scientist,
Respiratory and Inflammation, Schering-Plough
Research Institute
Navin L. Rao, PhD, Senior Scientist, Drug
www.iqpc.com/us/asthma Discovery, Inflammation, Johnson & Johnson

2. Asthma Gain valuable insights into new groundbreaking advances
within the respiratory drug development market
& COPD
TM
June 24-26, 2009 | Philadelphia, PA
Who Will you Meet at the
Conference?
Directors, Heads, Scientists, Chemists,
Research Leaders/Fellows/Advisors, &
Managers working in the pharmaceutical or
Dear Colleagues, biotech industries within:
Respiratory Therapeutics
•
Respiratory diseases including Asth Research & Development
•
ma are becoming more common,
especially in
children, therefore the demand for Inflammation
•
continued development in respirato
ry drug Clinical Development
discovery and development arena •
has grown significantly in recent year
s. The Regulatory Affairs
•
commercial drug development mar
ket in this area continues to grow Pulmonology
with inhaled •
corticosteroid/long-acting bronchod
ilator combinations set to be the lead Drug Discovery
•
ing class by
value in 2014, and an estimated 300
million people in the world will be Respiratory Illness
•
suffering
from Asthma, with COPD on the
rise. Drug Delivery
•
Project Management
•
This year’s timely conference will cove Allergy Therapeutics
•
r over 16 in-depth sessions and case
study
examples including: Preclinical Development
•
Portfolio/Lifecycle Management
•
• Novel Tech
niques for Formulating a Respirato
ry Drug Development Pipeline
• Differences
in the Development of Small vs. Larg
e Molecules
A special thank you to our
• Evolving Clin
ical Endpoints in the Developmen
t of Inhaled Corticosteroids
advisory board
• Clinical Out
comes of PD4 Inhibitors: Valuable
Lessons Learned
• Improving
the Management of Patient Care Kevin B. Bacon, PhD, President, Founder and
in Asthma Chief Scientific Officer, Axikin
• Developing
Product Design for Addressing Patie
nt Adherence and Compliance Pharmaceuticals
Heribert Staudinger, PhD, Vice President,
And much more including 4+ hou Clinical Development, Schering Plough
rs of scheduled networking, insightfu
l interactive
panel discussions and a series of inte Shahin Sanjar, PhD, Head, Pipeline Sourcing,
ractive workshops.
Nycomed US Inc.
Mark Parry-Billings, PhD, Chief Executive
Engage in dynamic conversation with
your industry peers at our multiple Officer, Topigen Pharmaceuticals
networking
sessions and work closely with man
y respiratory drug discovery and deve Ewan Walters, PhD, Medical Director, Teva UK
lopment
industry leaders including AstraZen
eca, Merck, Johnson & Johnson, Med Dzelal Serdarevic, PhD, Director, A&R
Immune,
Schering Plough, Nycomed, GlaxoSm Therapeutic Area, Clinical R&D, Pfizer
ithKline, Novartis and many more,
including a
series of medical device designers, Reza Farienfar, Director, Business
delivery experts and academic part
icipants. Be
sure to register yourself and a team Development, Cardinal Health
of key people for this important even
t today! Gerhard Scheuch, PhD, Chief Executive
Officer, Activaero GmbH
We look forward to seeing you in
Philadelphia in June!
Best Regards,
Sponsorship and Exhibition
Opportunities
teractive
P . - Highly in
Sponsorships and exhibits are excellent
.S opportunities for your company to showcase its
e
and informativ products and services to high-level, targeted
rence decision-makers attending the Asthma & COPD
post-confe
e page 5 Summit. IQPC and Pharma IQ help companies like
workshops! Se
Simon Curtis yours achieve important sales, marketing and
branding objectives by setting aside a limited
for details.
Conference Director
number of event sponsorships and exhibit spaces –
www.iqpc.com/us/asthma all of which are tailored to assist your organization
in creating a platform to maximize your exposure at
the event.
For more information on sponsoring or exhibiting at
the Asthma & COPD Summit please contact Mario
Matulich at (212) 885-2719 or
sponsorship@iqpc.com.
1-800-882-8684 • www.iqpc.com/us/asthma
2

3. Main Conference Day One
Wednesday, June 24, 2009
Registration and Coffee Evaluating high resolution CT scans
•
8:00
Identifying newer endpoints for evaluation
•
Welcome Address and Chairman’s Opening Remarks Kevin B. Bacon, PhD, President, Founder and Chief Scientific Officer,
8:50
Axikin Pharmaceuticals
Opening Keynote Presentation: Novel Techniques for Heribert Staudinger, PhD, Vice President, Clinical Development,
9:00
Formulating a Respiratory Drug Development Pipeline Schering Plough
Fred Bode, PhD, Director, Respiratory Sciences, Sepracor*
Accelerating the drug development pipeline
•
Shahin Sanjar, PhD, Senior Director, Respiratory Sciences, Nycomed
Identifying a set of promising candidate projects addressing gaps in several
•
stages of the drug development pipeline from fundamental research to
Evolving Clinical Endpoints in the Development of
2:15
product
Inhaled Corticosteroids
Evaluating strategies for generating large numbers of molecular targets for
•
Discussing development of inhaled corticosteroid/long-acting beta-
•
drugs as well as novel molecules to attack new and existing drug targets
agonist combinations
• Generating the interest and funding that will move a compound along
• Overviewing clinical endpoints
the path to eventual therapeutic approval
• Addressing and understanding beta-agonist safety issues/patient
Theodore F. Reiss, MD, Vice President of Clinical Research, Merck
monitoring
Research Laboratories
• Examining endpoint case study examples
Panel Discussion: Understanding and Assessing the Need • Discussing the development of NMEs in asthma and COPD
9:45
for New Drug Development Pipelines in the Respiratory • Discovering if we need new bronchodilators and anti-inflammatory
Market drugs for the treatment of asthma and COPD
Heribert Staudinger, PhD, Vice President, Clinical Development,
Examining pipeline pitfalls from the past: What to be aware of?
•
Schering Plough
Overviewing new respiratory therapeutic approaches: Strategies for
•
predicting clinical success or failure
Networking Break
3:00
• Investigating compounds which may help improve control of asthma
exacerbations while reducing the need for steroids and rescue medication
The Promise of PDE4 Inhibitors as Novel Anti-
3:30
• Evaluating the need to find novel anti-inflammatory drugs to treat COPD
Inflammatory Agents in COPD: Valuable Lessons Learnt
to reduce exacerbations, disease progression and mortality
From Clinical Studies
• Discussing and predicting the future direction of the respiratory drug
Discussing what we can learn from animal models of COPD
•
discovery and development market
Identifying what we have learnt from clinical studies with PDE4
•
Nestor A. Molfino, MD, Vice President, Clinical Development, Respiratory
inhibitors
Diseases, Allergy and Inflammation, MedImmune
• Choosing appropriate endpoints to reflect the drug mode of action
Mark Parry-Billings, PhD, Chief Executive Officer, Topigen
• Treating systemic or lung disease
Adam Wanner, MD, Professor, Principal Investigator, University of
• Examining the place of anti-inflammatory therapy in COPD
Miami Miller School of Medicine
Shahin Sanjar, PhD, Head, Pipeline Sourcing, Nycomed US Inc.
Networking Break
10:30
Application of Antisense Oligonucleotides in Asthma
4:15
and COPD (Case Study)
Differences in the Development of Small vs. Large
11:00
Molecules Examining oligonucleotide therapeutics in respiratory disease
•
Displaying rationale for using a multi-target approach in asthma and
•
Summarizing the main differences between small molecules and large
•
COPD
molecules
• Designing and pre-clinical screening of effective drug candidates
• Reviewing of preclinical approaches
• Discussing clinical positioning and findings
• Understanding of main differences in clinical development programs
Mark Parry-Billings, PhD, Chief Executive Officer, Topigen
• Exploring if combination of large and small molecules is feasible
• Comprehending the major bottlenecks in overall development
COPD: New Lessons from Alpha-1 Antitrypsin
5:00
Nestor A. Molfino, MD, Vice President, Clinical Development, Respiratory
Deficiency (Case Study)
Diseases, Allergy and Inflammation, MedImmune
Appreciating the global COPD problem and the lack of disease-
•
Functional Endpoints in Asthma modifying drug therapy for COPD
11:45
• Understanding that alpha-1 antitrypsin deficiency, a rare genetic
Discussing lung function use as a primary endpoint in asthma clinical trials
•
disease with a well characterized pathogenesis, has the same
Discussing relationships between, traditional and patient-centered end-
•
pulmonary phenotype as common COPD and therefore can serve as
points during treatment with different classes of medication
an experiment of nature to study the pathogenesis of common COPD
• Examining severe asthma indicated by poor lung function, frequent
• Appreciating the fact that the concept of protease-antiprotease
symptoms or reliever use, night waking and exacerbations
imbalance, thought to be shared by alpha-1 antitrypsin deficiency and
• Understanding the relationship between end-points and medication class
common COPD, has not resulted in effective drugs for COPD
• Identifying novel functional endpoints in Asthma with case study
• Becoming familiar with protein misfolding, aggregation and disposal,
examples
a new link between alpha-1 antitrypsin deficiency and common COPD
Chris O’Brien, PhD, Vice President, Respiratory & Inflammation Therapeutic
• Understanding that pharmacologically targeting protein misfolding
Area, AstraZeneca
and trafficking could lead to the development of novel drugs for both
Networking Lunch alpha-1 antitrypsin deficiency and common COPD
12:30
Adam Wanner, MD, Professor, Principal Investigator, University of
Panel Discussion: Improving Endpoints in COPD Drug Miami Miller School of Medicine
1:30
Development
End of Day One
5:45
Discussing the pros and cons of improved X-Ray analysis
•
1-800-882-8684 • www.iqpc.com/us/asthma
3

4. Main Conference Day Two
Thursday, June 25, 2009
Registration and Coffee Novel Ion Channel Drug Development Strategies
8:00 1:30
for the Treatment of COPD Symptoms
Welcome Address and Chairman’s Opening
8:50 Displaying the use of RNA interference for in vivo pre-clinical
•
Remarks validation of ion channel targets in non-mouse species
• Understanding automated patch-clamp and baculovirus-based
Developing Product Design for Addressing Patient
9:00 vectors for transient transfection as enabling technologies for
Adherence and Compliance ion channel drug discovery
Retaining current patients as costs six times more to attract • Discussing recent insights into the molecular biology and
•
new patients function of the airway nociceptor and its links to cough,
• Discovering and uncovering specific design requirements for dyspnea and other respiratory symptoms
tackling adherence and compliance • Examining tetrodotoxin-resistant sodium channels and transient
• Understanding which medical device designer and receptor potential channels as emerging therapeutic targets for
manufacturer is a good fit for your product, and why chronic respiratory diseases
• Applying sophisticated analytical processes to quantify the sales • Identifying translational aspects of targeting ion channels for
impact of specific marketing programs for product brands COPD symptom relief
• Examining product design success stories and case study M. Allen McAlexander, PhD, Investigator, Respiratory CEDD,
examples post patient usage GlaxoSmithKline
Please check the website for speaker updates.
Formulation, Generation and Delivery of
2:15
Improving the Management of Patient Care in Respiratory Therapeutic Aerosols to Rodents
9:45
Asthma Discussing the use of animal disease models as a tool for
•
Improving communication and understanding between patients assessing efficacy of inhaled pre-clinical drug candidates
•
and physicians • Overview of instrumentation necessary to deliver dry powder
• Examining patient suggestions for improvements aerosols to rodents and estimated the dose delivered to the
• Improving education around the illness and treatment lungs
• Discussing the benefits of more than one pharmacological • Identifying ideal properties of inhaled respiratory drugs
approach • Displaying case study examples of using this model with clinical
Colin Scott, MD, Global Brand Medical Director, Novartis standard inhaled steroids
Jonathan E. Phillips, Ph.D, Principal Scientist, Respiratory Drug
10:30 Networking Break Discovery, Schering-Plough Research Institute
11:00 Novel Inhaled Drug Delivery Technology Networking Break
3:00
• Evaluating the effectiveness of Inhalation of bronchodilators
Leukocyte Proteases in Airways Diseases (Case
and glucocorticosteroids 3:30
Study)
• Minimizing local (oropharyngeal) and systemic side-effects of
drugs Protease-protease inhibitor imbalance contributes to airways
•
• Uncovering simple to use, portable, durable, unobtrusive and diseases such as asthma and COPD
cost effective medical device aspects • Neutrophil derived Cathepsin G and mast cell derived chymase
• Examining the pros and cons of the pressurized metered-dose and tryptase may be key enzymes contributing to these
inhaler (pMDI) - The most widely used delivery system diseases
• Discussing the increased-use of DPIs (Dry-powder Inhalers) to • Small molecule inhibitors of these enzymes have anti-
deliver asthma medications inflammatory properties and are effective in preclinical models
Please check the website for speaker updates. of airways diseases
Lawrence de Garavilla, Ph.D., Research Fellow, Inflammation
11:45 Using Patents Strategically in Respiratory Product and Pulmonary Diseases Team, Drug Discovery, Johnson &
Lifecycle Management Johnson Pharmaceutical Research and Development, L.L.C.
Learning how innovators and generics are using patents to
•
Leukotriene A4 Hydrolase Inhibitors and Airway
manage lifecycles 4:15
Inflammation (Case Study)
• Discussing patents on combination drugs in the current
environment Overview of leukotriene A4 hydrolase biology
•
• Using novel delivery systems—both pharmaceutical and Efficacy of leukotriene A4 hydrolase inhibitors in preclinical
•
devices—as a basis for patent protection airway inflammation models
• Getting competitive intelligence, patent strategy, and product • Understanding the role of leukotrienes in chronic airway
strategy to work together models
Bruce D. Sunstein, Co-founder, Partner, • Displaying mechanisms of action of leukotriene A4 hydrolase
Bromberg & Sunstein LLP inhibitors
Navin L. Rao, PhD, Senior Scientist, Drug Discovery,
12:30 Networking Lunch Inflammation, Johnson & Johnson
End of Conference & Chairman’s Closing Remarks
5:00
1-800-882-8684 • www.iqpc.com/us/asthma
4

5. Post-Conference Workshops
Friday, June 26, 2009
9:00 am – 12:00 pm (Registration at 8:30 am) Coffee will be served 12:30 pm – 3:00 pm (Registration at 12:00 pm) Lunch included
A B
The Effective Use of Biomarkers in Asthma and Allergy issues: Addressing
Respiratory Drug Discovery Approaches to Allergic Disorders
Studying clinical effects of new therapies on patients through Currently within the respiratory arena, there have been modern
electronic monitoring of lung function (FEV1) as well as misconceptions why asthma–related drug development
advanced lung function and exercise and challenge test has programs have not been pursued commercially in the form of
become possible. As a result of this., respiratory drug tackling other similar allergy-therapeutic disorders. Given that,
development companies are employing human whole blood there are many similarities between both asthma-based drug
flow cytometry and non-invasive sampling to assess therapeutics and many allergy-based drug development
pharmacodynamic effects of new therapies in phase I/II clinicial programs. This workshop will uncover and overview some of the
studies. Surrogate biomarkers in COPD may be assessed in novel approaches to these new drug development pipelines
blood, exhaled breath, induced sputum, bronchial mucosal focused on allergy therapeutics, and identify some of the most
biopsy, bronchoalveolar lavage (BAL), and through advanced commercially viable pipelines currently in development.
radiographic imaging.
What will be covered:
What will be covered: • Displaying novel approaches for identifying genes responsible
• Making a suited claim to the FDA for therapeutic purposes for allergic disorders
• Identifying and understanding new biotechnology agents and • Discussing standardized immuno-therapeutic approaches for
biomarkers for asthma allergies
• Studying clinical effects of new therapies on patients through • Evaluating unorthodox testing methods:
electronic monitoring of lung function (FEV1) 1. Vega (electro-diagnostic) testing
• Employing human whole blood flow cytometry and non- 2. Cytotoxic testing (quot;Bryan's testquot;) and the Alcat test
invasive sampling to assess pharmacodynamic effects of new 3. Iridology
therapies in phase I/II clinical studies 4. Kinesiology
• Relying on a collaboration between academics in clinical 5. IgG food antibody testing and other techniques
research, the pharmaceutical industry and regulatory • Developments in allergy elimination techniques - allergen
authorities immunotherapy
• Uncovering the link between allergic disorders and asthma
Workshop Leaders: approaches
Yi Wang, PhD, Head, Preclinical Sciences, Alexion
Pharmaceuticals Please check the website for up-to-date details about
Marianne Mann, MD, Clinical & Regulatory Drug Development the workshop.
Consultant
Please check the website for up-to-date details about
the workshop.
About the Media Partners
A major STM publisher, Bentham Science answers the information needs for the pharmaceutical, Bio-medical and medical research
community. Leading journals include Current Pharmaceutical Design (Impact Factor 4.8) and Current Medicinal Chemistry (Impact
Factor 4.9) FREE online journals & information: www.bentham.org
Since 1999, PharmiWeb.com has been bringing the latest news and developments in the pharmaceutical industry to a global
audience, now reaching close to a quarter of a million professionals. Sponsored by many of the world’s leading pharmaceutical
corporations, PharmiWeb.com is widely regarded as the leading pharma portal. To find out more about PharmiwWeb.com, and the
other offerings from PharmiWeb solutions, please visit www.pharmiwebsolutions.com.
Piribo is a UK-based independent online store supplying business information on the pharmaceutical and biotechnology industries.
The website now carries nearly 10,000 English language titles including, market reports, studies and books and is the UK's largest
online biopharma information store. www.piribo.com
Report Buyer is the intelligent way to buy market research online. Browse and choose from a current and comprehensive range of
specialised intelligence from leading publishers covering most industry and market sectors. Trusted by information professionals
across the world, Report Buyer’s mission is to help you find the right business intelligence. www.reportbuyer.com
1-800-882-8684 • www.iqpc.com/us/asthma
5

6. Asthma Gain valuable insights into new
groundbreaking advances within the
respiratory drug development market
& COPD
TM
June 24-26, 2009
Philadelphia, PA
REGISTRATION CARD (Email this form to info@iqpc.com or fax to 646-378-6025)
YES! Please register me for
❑ Conference Only ❑ All-Access Pass ❑ Workshops
Name ____________________________________________________________ Job Title _________________________________________________
Organization______________________________________________________ Approving Manager________________________________________
Address _____________________________________________ City________________________________________State__________Zip__________
Phone_____________________________________________E-mail____________________________________________________________________
❑ Please keep me informed via email about this and other related events.
❑ Check enclosed for $_________ (Payable to IQPC) ❑ Charge my ❑ Amex ❑ Visa ❑Mastercard ❑ Diners Club
Card #_______________________________Exp. Date___/___
❑ I cannot attend, but please keep me informed of all future events.
Registration Information
Qualified Pharmaceutical and Biotech Organizations:
PRICING Register by April 3, 2009 Register by April 17, 2009 Register by May 1, 2009 Register by May 29, 2009 Standard Price
Conference Only $1,199 (save $400) $1,299 (save $300) $1,399 (save $200) $1,499 (save $100) $1,599
All-Access Pass $1,999 (save $698) $2,099 (save $598) $2,199 (save $498) $2,299 (save $398) $2,399 (save $298)
Workshops $549 each $549 each $549 each $549 each $549 each
Others:
PRICING Register by May 1, 2009 Register by May 29, 2009 Standard Price
Conference Only $1,999 (save $600) $2,299 (save $300) $2,599
All-Access Pass $2,899 (save $798) $3,199 (save $498) $3,499 (save $198)
Workshops $549 each $549 each $549 each
See website at www.iqpc.com/us/asthma for an explanation of a Qualified Pharmaceutical and Biotech Organizations.
Please note multiple discounts cannot be combined. Reference: Please include the name of the attendee(s) and the event number: 17336.001
A $99 processing charge will be assessed to all registrations not Payment Policy: Payment is due in full at the time of registration and includes lunches, refreshment
accompanied by credit card payment at the time of registration. and detailed conference materials. Your registration will not be confirmed until payment is received
and may be subject to cancellation.
MAKE CHECKS PAYABLE IN U.S. DOLLARS TO: IQPC
* CT residents or people employed in the state of CT must add 6% sales tax. For IQPC’s Cancellation, Postponement and Substitution Policy, please visit
www.iqpc.com/cancellation
TEAM DISCOUNTS
or information on team discounts, please contact IQPC Customer Service at Note: Conference venue to be confirmed shortly. Please check www.iqpc.com/us/asthma for updated
1-800-882-8684. Only one discount may be applied per registrant. information.
Special Discounts Available: A limited number of discounts are available Special Dietary Needs: If you have a dietary restriction, please contact Customer Service at 1-800-882-
for the non-profit sector, government organizations and academia. For more 8684 to discuss your specific needs.
information, please contact customer service at 1-800-882-8684.
©2009 IQPC. All Rights Reserved. The format, design, content and arrangement of this brochure
Details for making payment via EFT or wire transfer: constitute a trademark of IQPC. Unauthorized reproduction will be actionable under the Lanham Act
JPMorgan Chase - Penton Learning Systems LLC dba IQPC: 957-097239 and common law principles.
ABA/Routing #: 021000021
1-800-882-8684 • www.iqpc.com/us/asthma
6